Compounds > nafamostat
Page last updated: 2024-10-31

nafamostat and Acquired Autoimmune Hemolytic Anemia

nafamostat has been researched along with Acquired Autoimmune Hemolytic Anemia in 2 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yamamura, M1
Miyamoto, T1
Yao, H1
Ijichi, S1
Sano, Y1
Une, F1
Maruyama, I1
Osame, M1

Other Studies

2 other studies available for nafamostat and Acquired Autoimmune Hemolytic Anemia

ArticleYear
Open heart surgery in a patient with autoimmune hemolytic anemia.
    The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi, 1999, Volume: 47, Issue:5

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Benzamidines; Betamethasone; Cardiopu

1999
[Accessory use of protease-inhibiting agents for disease remission in a patient with autoimmune hemolytic anemia associated with B-CLL].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1990, Volume: 31, Issue:2

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Benzamidines; Complement Activation; Complement Inactivator Pro

1990